Esansiyel Hipertansiyonlu Hastalarda Enalapril Tedavisinin Böbrek Fonksiyonlarına etkisi

Abstract

We have studied the effects of an angiotensin-converting enzyme inhibitor, enalapril on systemic blood pressure and renal function in 15 patients with essential hypertension without clinical renal involvement. Systolic and diastolic blood pressures were significantly reduced during the study compared with pretreatment values (respectively p< 0.01 and p = 0.001). After a mean of 3.2 months of therapy, enalapril caused significantly decrease in microproteinuria (from 188.00 + 88.12 to 159.47 + 79.57 mg/giin, p< 0.01), and in serum uric acid (from 6.05 = 1.07 to 5.87 + 1.09 mg/dl, p< 0.05). Serum creatinine, blood urea nitrogen, and creatinine clearance were remained unchanged. By the enalapril therapy, serum sodium level was significantly decreased (p< 0.05), and serum potassium level was increased (p = 0.05). The changes in microproteinuria values during the study were significantly and positively correlated with concurrent changes in serum uric acid levels (r = 0.621, p= 0.01), However, the changes in microproteinuria and serum uric acid were not correlathe declines of systolic and diastolic blood pressure. Our data suggest that in addition to lowering and controlling systemic blood pressure, enalapril therapy may provide a renal protective effect.

Keywords

• Essential hypertension
• Enalapril
• Serum uric acid
• Microproteinuria.

Esansiyel Hipertansiyonlu Hastalarda Enalapril Tedavisinin Böbrek Fonksiyonlarına etkisi

Abstract

Biz, klinik bébrek tutulumu bulunmayan 15 esansiyel hipertansiyonlu hastada bir «anjiotensin converting enzim» inhibitérii olan enalaprilin sistemik kan basinci ve bébrek fonksiyonlar: Uzerine etkilerini inceledik. Calisma esnasinda sistolik ve diastolik kan basinglarin da tedavi öncesi değerlere göre anlamlı azalma olmuştur {sırasıyla p< 0.01 ve p = 0.001). Ortalama 3.2 ayhk tedaviden sonra, enalapril mikroproteintiride (188.00 + 88.12’den 159.47 + 79.57 mg/gtn’e, p<0.01) ve serum tirik asitinde (6.05 + 1.07'den 5.87 = 1.09 mg/dl’ye, p<0.05) anlamli azalmalara yol acmuistir. Serum kreatinin, BUN ve kreatinin klirenste degisiklik olmamustir. Enalapril tedavisi ile serum sodyum düzeyi anlamlı olarak azalmış (p< 0.05), serum potasyum düzeyi ise artmıştır (p = 0.05), Calisma esnasinda mikroproteinuri degerlerinde gözlenen değişiklikler serum ürik asit dizeyindeki eş zamanlı degisikliklerle anlam ve pozitif olarak korelasyon göstermektedir (r = 0.621, p = 0.01). Ancak, mikroproteinuri ve serum lirik asitindeki değişiklikler sistolik ve diastolik kan basınlarındaki azalmalar ile korelasyon göstermemektedir, Verilerimiz, sistemik kan basıncının, azalması ve kontrolüne ilave olarak, enalaprilin böbrek koruyucu bir etki gösterebildiğini düşündürmektedir.

Keywords

• Esansiyel hipertansiyon
• Enalapril
• Serum irik asiti
• Mikroproteintri.

References

1. 1. Amery A Birkenhager W Brixko P et al : Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. Lancet 1; 1849-1354, 1985. 2. Anderson S Meyer TW Rennke HG Brenner BM: Control of glomerular hypertension limits in glomerular injury in rats with reduced renal mass. J Clin Invest 76 : 612619, 1985. 3. Aurell M : Aspects of the role of intraglomerular pressure as a cause of progressive renal damage. Drugs 35 (suppl 5) : 42-47, 1988.
2. 4. Bauer JH Reams GP : Renal protective effect of long term antihypertensive therapy with enalapril. Drugs 35 (suppl 5) : 62-71, 1988.
3. 5. Bauer JH Reams GP Wu Z: The aging hypertensive kidney : Pathophysiology and therapeutic options. Am J Med 80 (suppl 4B) : 21-27, 1991.
4. 6. Bauer JH Reams GP : ACE inhibitors in renal disease. Clin Cardiol 14 (suppl IV) ; 38-43, 1991.
5. 7.Bradford MM : A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 ; 248-251, 1976,
6. 8. Brazy PC Stead WW Fitzwilliam JF : Progression of renal insufficiency : Role of blood pressure. Kidney Int, 35 : 670-674, 1989.
7. 9. De Leeuw PW : Renal function in the elderly : Results from the European Working Party on high blood pressure in the elderly trial. Am J Med 90 (suppl 3A) : 45-49, 1991.
8. 10. Dzau VJ Ingilfinger JR : Molecular biology and pathophysiology of the intrarenal renin-angiotensin system. J Hypertens 7 (suppl 7) : 53-58, 1989.

9. 11. Excerpts from United States Renal Data System 1990 Annual Report : III. Causes of end stage renal disease. Am J Kidney Dis 16 (suppl 2) : 22-27, 1990.
10. 12. Ferris TF Gorden P : Effect of angiotensin and norepinephrine upon urate clearance in man. Am J Med 44 : 359-365, 1968
11. 13. Giuntoli F Gabbani 5 Natali A et al : Captopril treatment in elderly hyperten
12. 14. Giuntoli F Gabbani 5 Natali A et al : Captopril treatment in elderly hypertensive patients : Efficacy and tolerability. J Hypertens 7 (suppl 7) : 57-58, 1989,
13. 15. Hall JE : Control of sodium excretion by angiotensin II : Intrarenal mechanisms
14. 16.Hollenberg NK Borucki LJ Adams DF : The renal vasculature in early essential hypertension ; Evidence for a pathogenetic role. Medicine 57 : 167-178, 1978.
15. 17.Ikoma M Kawamura T Kakinuma Y et al : Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 40: 105-202, 1091.
16. 18. Ljungman S Aurell M Hartford M et al : Effect of subpressor dose of angiotensin II on renal hemodynamics in relation to blood pressure. Hypertension 5 : 368-374, 1983
17. 19. London GM Safar ME Sassard JE et al: Renal and systemic hemodynamics in sustained essentiel hypertension. Hypertension 6: 743-754, 1984.
18. 20. Marie M Sassano P Corvol P et al: Microalbuminuria in uncomplicated essential hypertension and its reduction by antihypertensive treatment. Diabete Me-tab 14 : 232-234. 1988
19. 21. Mazzuca N Bigazzi R Paparatto Pet al: Effects of enalapril on urinary protein excretion of essential and renal parenchymal hypertensive patients. Comparison between colorimetric and radioimmunological methods. J Nucl Med Allied Sci32; 75-81, 1883.
20. 22. McNabb WR Noormohamed FH Lant AF: The effects of enalapril on blood pressure and the kidney in normotensive subjects under altered sodium balan-ce. J Hypertens 4: 39-47, 1986.
21. 23. Medical Research Council Working Party : MRC trial of treatment of mild hypertension principle results. Br Med J 291 : 97-104, 1085.
22. 24. Messerli FH Frohlich ED Dreslinski GR et al: Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Ann Intern Med93 : 817-821, 1980.
23. 25. Raij L Azar S Keane WF: Mesangial immune injury, hypertension and progressive glomerular damage in Dahl rats. Kidney Int 26: 137-143, 1984.
24. 26. Ralj L Shultz PJ Tolins JP: Possible mechanism for the protective effect of angiotensin converting enzyme inhibitors. J Hypertens 7 (suppl 7) : 33-37, 1989.
25. 27. Rodicio JL Praga M Alcazar JM et al: Effects of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans.J Hypertens 7 (suppl 7) : 43-47, 1989.
26. 28. Rostand SG Brown G Kirk KA et al: Renal insufficiency in treated essential hypertension. N Engl J Med 320: 684-888, 1989.
27. 29. Ruilope LM Miranda B Oliet A et al: Control of hypertension with the angiotensin converting enzyme inhibitor captopril reduces glomerular proteinuria.J Hypertens 6 (suppl 4) : 87-69, 1988.
28. 30. Rüddel H Bahr M Langewitz W et al: Efficacy of long-term antihypertensive therapy with enalapril. Nephron 55 (suppl I) : 77-80, 1990.
29. 31. Schwartz GL Cameron GS: Renal parenchymal involvement in essential hyper-tension. Medical Clinics of North America 71 : 843-858, 1987.Shulman NB Ford CE Hall WD et al: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: Results from the Hypertension Detection and Follow-up Program. Hypertension 13 (suppl I) : 80-93,1989.
30. 33. Tykarski A : Evaluation of renal handling of uric acid in essential hyperten-sion: Hyperuricemia related to decreased urate secretion. Nephron 59: 364-368,
31. 34. Warner NJ Rush JE: Safety profiles of the angiotensin converting enzyme in-hibitors. Drugs 35 (suppl 5) : 89-97, 1988.
32. 35. Weinman EJ: Renal handling of uric acid. In Textbook of Nephrology. Massry SG, Glassock RJ (eds). Second edition Williams and Wilkins, Baltimore, 1989, pp 92-93.